



THE INTERNATIONAL JOURNAL OF

# CLINICAL PRACTICE

**IJCP** JUNE 2020 VOLUME 74 NUMBER 6

ISSN 1368-5031 (print) ISSN 1742-1241 (online)



**WILEY**

# EDITORS

## EDITOR-IN-CHIEF

Charles Young, BSc (Hons), MBBS (Hons), MRCP, *Senior Medical Officer, Capita and Emergency Physician, St Thomas' Hospital, London, UK*

## SENIOR EDITORS

### General/surgery/internal

Dan-Sebastian Dirzu, MD, PhD, *Iuliu Hatieganu University of Medicine and Pharmacy, Romania*

### Urology

Matt Rosenberg, MD, BA, *Medical Director, Mid-Michigan Health Centers, Jackson, MI, USA*

### Infectious Disease

Richard Stein, MD, PhD, *New York University School of Medicine, USA*

### Metabolism, Diabetes and Endocrinology

George Thomson, *Consultant Endocrinologist, NHS, UK*

### Obstetrics & Gynaecology

Angela Vinturache, MD, PhD, *Oxford University Hospital NHS Foundation Trust, Oxford, UK*

### Healthcare Administration

William Deary, *Community & Home-Based Health Care, USA*

### Rheumatology

Lindsay MacFarlane, *Harvard Medical School, USA*

### Cardiology / Cardiovascular disease

Gregory Lip, *University of Liverpool, UK*

### Ear, Nose and Throat

Magdalena Chirila, *Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania*

### Gastroenterology

John Findlay, *North Devon District Hospital, UK*

### Rheumatology (plus osteoarthritis)

Lindsay MacFarlane, *Harvard Medical School, USA*

## EDITOR EMERITUS

Graham Jackson, MD, FESC, FRCP, FACC, *Consultant Cardiologist, Guy's and St Thomas' Hospital, London, UK*

Leslie Citrome, MD, MPH, *Clinical Professor of Psychiatry & Behavioral Sciences, New York Medical College, Valhalla, NY, USA*

## EDITORIAL BOARD

Intekhab Ahmed, *Philadelphia, PA, USA*

Stavros Apostolakis, *Birmingham, UK*

John Chambers, *London, UK*

Christopher Chapple, *Sheffield, UK*

Magdalena Chirila, *Cluj-Napoca, Romania*

Hans-Christoph Diener, *Essen, Germany*

M. Hamed Farooqi, *Dubai, UAE*

Albert Ferro, *London, UK*

Jonathan Foulds, *New Brunswick, NJ, USA*

Bob Hancox, *Dunedin, New Zealand*

Katrine Bagge Hansen, *Copenhagen, Denmark*

Joshua Kantrowitz, *New York, USA*

David Katz, *Jerusalem, Israel*

Michael Kirby, *Herts, UK*

Gregory Lip, *Birmingham, UK*

Martin Miner, *Providence, RI, USA*

Rita Nemr, *Beirut, Lebanon*

Macaulay Onuigbo, *Wisconsin, WI, USA*

Basant Puri, *London, UK*

Senaka Rajapakse, *Lincolnshire, UK*

Gregory Ruhnke, *Chicago, IL, USA*

Pertti Saloheimo, *Espoo, Finland*

David Taylor, *London, UK*

Adie Viljoen, *Hertfordshire, UK*

## Editorial Office

Robert Huston

[ijcp\\_editorial@wiley.com](mailto:ijcp_editorial@wiley.com)

## Production Editor

Florie L. Canales

[ijcpproduction@wiley.com](mailto:ijcpproduction@wiley.com)

## Publisher

Rosie Levermore

John Wiley & Sons Inc.

9600 Garsington Road

Oxford, OX4 2DQ

UK

Tel +44 1865 47 6517

[rlevermore@wiley.com](mailto:rlevermore@wiley.com)

## Enquiries for

Advertising: Neil Chesher

Tel +44 (0)1865 476 383

Commercial sales: Tobias Trinkl

Tel +49 30 4703 1468

Marketing: Hannah Qualtrough

Tel: +44 1865 47 6396

Reprints: Liz Day

Tel +44 (0)1865 476 355

## Internationally referenced:

- MEDLINE/PubMed
- EMBASE (Excerpta Medica)
- ISI, Current Contents

# NOTES FOR CONTRIBUTORS on [www.IJCP.org](http://www.IJCP.org)

- **EXPEDITED:** The new priority service from *IJCP* exclusively for clinical trials.
- **Timelines.** Rapid, robust peer review and publication – more information is online.
- **Early View.** The fastest form of publication online ahead of print.
- **OnlineOpen.** Ensure that your article is immediately and permanently made free to access online.
- **OnlineExtra supporting information.** Slideshows and other material to help explain and illustrate key concepts.
- **Medscape.** Content syndication in partnership with Medscape.com delivers *IJCP* authors broader reach, notably in the US, by free online distribution.
- **Volume Contents.** Volume contents will no longer be published for *IJCP*. However, the table of contents can be found within each issue and this information is available online.

## Aims and Scope

*IJCP* is a general medical journal. *IJCP* gives special priority to work that has international appeal. *IJCP* encourages enquiries from potential contributors prior to formal submission ([ijcp\\_editorial@wiley.com](mailto:ijcp_editorial@wiley.com)).

## Disclaimer

The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher and Editors of the products advertised.

## Copyright and Copying

Copyright © 2020 John Wiley & Sons Ltd. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization

to copy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA ([www.copyright.com](http://www.copyright.com)), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: [permissions@wiley.com](mailto:permissions@wiley.com)

*International Journal of Clinical Practice* accepts articles for Open Access publication. Please see <http://olabout.wiley.com/WileyCDA/Section/id-406241.html> and select author guidelines for further information about OnlineOpen.

Cover image reproduced by kind permission of Kristoffer Magnusson, <http://rpsychologist.com/>

**Systematic Review**

- e13462 What are physiotherapists and occupational therapists doing in services that replace acute hospital admission? A systematic review  
*C. Harris, A. Ignatowicz, D. S. Lasserson*

**Meta-Analysis**

- e13490 Effect of high-intensity interval training and continuous endurance training on peak oxygen uptake among seniors aged 65 or older: A meta-analysis of randomized controlled trials  
*W. Bouaziz, A. Malgoyre, E. Schmitt, P.O. Lang, T. Vogel, L. Kanagaratnam*
- e13493 Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials  
*M. Vajdi, M. Abbasalizad Farhangi*

**Original Papers**

- e13483 Minor bleeding affects the level of knowledge in patients with atrial fibrillation on oral anticoagulant therapy  
*A. Metzgieer-Gumiela, G. Skonieczny, M. Koniecznyńska, L. Desteghe, H. Heidebuchel, A. Undas*
- e13484 Measuring stroke outcomes for 74 501 patients using linked administrative data: System-wide estimates and validation of 'home-time' as a surrogate measure of functional status  
*M. Gattellari, C. Goumas, B. Jalaludin, J. Worthington*

- e13485 Associations of fear of hypoglycemia with second-line use of insulin secretagogues or insulin and subsequent glycemic control in patients with type 2 diabetes: An analysis using data from the DISCOVER study  
*J.S. Wang, H. Chen, F. Tang, W.H. Sheu*

- e13489 Non-prescription medicines may contribute to non-adherence to prescription medicines in people living with chronic health conditions  
*S. Anoopkumar-Dukie, A. Mey, S. Hall, N. Bernaitis, A. K. Davey, D. Plummer*

- e13492 Baseline plasma lipid levels in patients with acute coronary syndrome: Association with 20-year mortality. The ABC-5a\*Study on Heart Disease  
*G. Berton, R. Cordiano, H. T. Mahmoud, R. Palmieri, F. Cavuto, M. Pasquinucci*

- e13494 Ultrasonographic measurements of the skin, fat and muscle in vitamin D deficiency  
*A. M. Ata, M. Kara, Ö. Kara, B. Kaymak, A. Akıncı, L. Özçakar*

- e13507 Laparoscopic management of bladder injury during total laparoscopic hysterectomy  
*C. Aydın, M. N. Mercimek*

**LETTER**

- e13487 Incapacitating, generalised myalgias and muscle stiffness under duloxetine and aripiprazole  
*J. Finsterer, W. Habitzl*



## ORIGINAL PAPER

Cardiovascular medicine

THE INTERNATIONAL JOURNAL OF  
CLINICAL PRACTICE WILEY

# Baseline plasma lipid levels in patients with acute coronary syndrome: Association with 20-year mortality. The ABC-5a\* Study on Heart Disease

Giuseppe Berton<sup>1,2</sup> | Rocco Cordiano<sup>2,3</sup> | Heba T. Mahmoud<sup>2</sup> | Rosa Palmieri<sup>2,3</sup> |  
Fiorella Cavuto<sup>2,4</sup> | Mattia Pasquinucci<sup>2</sup><sup>1</sup>Department of Cardiology, Conegliano General Hospital, Conegliano, Italy<sup>2</sup>The ABC Heart Disease Foundation-ONLUS, Conegliano, Italy<sup>3</sup>Department of Internal Medicine and Cardiology, Adria General Hospital, Adria, Italy<sup>4</sup>Department of Cardiology, Bassano del Grappa General Hospital, Bassano del Grappa, Italy**Correspondence**Giuseppe Berton, Department of Cardiology, Conegliano General Hospital, Via Brigata Bisagno, Conegliano 31015, Treviso, Italy.  
Email: giube.s@alice.it**Funding information**

This work was supported by a grant from Veneto Region, Italy (Veneto Region Act n. 748, Venice, May 14, 2015, grant number 298792) and from the University of Padova (Padova, Italy) for the data collection, management and analysis. The ABC Study on Heart Disease Foundation-ONLUS provided intellectual support to the present study.

**Abstract****Background:** The relationship between baseline plasma lipid levels during acute coronary syndrome and the outcome has clinical relevance.**Methods:** To evaluate their long-term prognostic value, we examined 589 patients admitted with acute coronary syndrome at three hospitals. Baseline plasma lipids were assessed on days 1 and 7. Patients were followed for 20 years or until death.**Results:** Virtually, all patients completed follow-up; 437 (74%) had died: 24% from coronary artery disease/heart failure (CAD/HF), 21% sudden cardiac death (SCD), 16% from other cardiovascular causes and 39% had non-cardiac death. The incidence rate (IR) of all-cause mortality was not different among patients with baseline plasma lipids less or greater than the median value. The IR of CAD/HF mortality was not significantly higher among patients with greater than median low-density lipoprotein (LDL) cholesterol and triglyceride (TG) levels. The IR of non-cardiac death tended to be lower among patients with greater than median total cholesterol (TC) and LDL levels. Using three levels of adjusted Cox survival models, baseline plasma lipids had no consistent independent or inverse association with all-cause mortality, even after excluding patients who received statins. Competitive risk survival models for each cause of death revealed that the only hazard of non-cardiac death was consistently higher among patients with less than or equal to median TC and LDL levels.**Conclusion:** In the present prospective long-term study, after acute coronary syndrome, baseline plasma lipid levels seem not to be associated with long-term global mortality. Only an independent inverse association between TC and LDL and non-cardiac death has been observed.

## 1 | INTRODUCTION

Ischaemic heart disease (IHD) is the world's biggest killer, accounting for 9.4 million deaths (16.6% of total deaths) in 2016 and has been the leading cause of death globally over the last 15 years.<sup>1</sup>High plasma lipid levels, particularly total serum cholesterol (TC) and low-density lipoprotein (LDL), have long been recognised as a major risk factor for atherosclerosis and IHD.<sup>2-4</sup> However, this causal relationship has been debated in recent reports.<sup>5-7</sup> The prognostic value of admission plasma lipid levels in patients presenting with acute coronary syndrome has rarely been discussed in the literature.<sup>8-10</sup> In the present study, we aimed to report the association

\*ABC is an acronym for Adria, Bassano, Conegliano, and Padova Hospitals.

between the in-hospital plasma lipid profile and the subsequent long-term mortality risk over 20 years of follow-up in an unselected sample of patients discharged alive from three different centres after an index hospitalisation with acute coronary syndrome.

## 2 | METHODS

### 2.1 | Patients

The ABC Study on Heart Disease is an ongoing prospective investigation designed to represent, as closely as possible, an unbiased population of patients with acute coronary syndrome ([www.abcheartdiseasestudy.org/en/](http://www.abcheartdiseasestudy.org/en/)). The cohort includes Caucasian patients with definite acute coronary syndrome, including ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) or unstable angina, who were admitted to the intensive care units of Adria, Bassano, and Conegliano General Hospitals in Italy between June 1995 and January 1998. The original aim of the ABC study was to monitor these patients with regard to natural long-term history, both non-fatal and fatal events, and causes of death. Another study aim was to investigate the prognostic value of multiple baseline clinical variables. Criteria for acute coronary syndrome diagnosis included clinical presentation, electrocardiogram findings and the presence of serum biochemical markers of necrosis.<sup>11,12</sup>

A total of 741 patients were considered eligible upon admission, 84 of whom were excluded because they had diseases other than acute coronary syndrome, and 23 were excluded because of a lack of baseline data. Among the 634 enrolled patients with acute coronary syndrome, 45 died during the index hospitalisation. Therefore, the postdischarge follow-up study included 589 patients (Figure 1). Each patient received an anonymous code, and no personal data or identifiers were included in the baseline or follow-up database. The study has been performed in accordance with the Declaration of Helsinki and it was approved by Adria, Bassano del Grappa and Conegliano General Hospitals ethics committee. All enrolled patients gave their written informed consent.

### 2.2 | Measurements and follow-up


At enrolment, a thorough patient history was collected from medical records and patient interviews. All presently analysed baseline clinical and laboratory data were obtained during the first 7 days of hospitalisation in the intensive coronary care unit. The acute coronary syndrome diagnosis criteria were the fulfilment of at least two of the following: central chest pain lasting >30 minutes, typical changes in serum enzymes, including total creatine kinase (CK) and creatine kinase MB (CK-MB), and typical electrocardiogram changes with pathological Q waves and/or localised ST-T changes in at least two contiguous leads.<sup>13</sup> Two fasting venous blood samples (12 hours after admission and before discharge) were drawn for TC, LDL, HDL, and triglyceride (TG) measurements. LDL concentrations were estimated

#### What's known

- In many studies, increased serum lipids are reported to be associated with a higher risk of mortality.

#### What's new

- After 20 years of follow-up of acute coronary syndrome survivors, baseline plasma lipid levels were not associated with all-cause mortality.
- Baseline plasma lipid levels were significantly inversely associated with death from non-cardiac causes.



**FIGURE 1** Flow diagram of the study population and progress during follow-up. ACS, acute coronary syndrome; CAD/HF, coronary artery disease/heart failure; Other CV, other cardiovascular causes; SCD, sudden cardiac death

using the modified Friedewald formula (MFF):  $LDL \text{ (mg/dL)} = \text{non-HDL} \times 90\% - \text{TG} \times 10\%$ . In all three hospitals, plasma lipid measurements were performed using an enzymatic colorimetric method.<sup>14</sup> Details of the measured variables were published previously.<sup>11,12</sup>

Each patient underwent a clinical check-up 1, 3, 5, 7, 10, 12, 15, 17 and 20 years after recruitment. At each recruitment hospital, two

cardiologists were responsible for monitoring the cohort of patients throughout the follow-up. Data were obtained from scheduled examinations, public administrations, hospital records, family doctors, postmortem examinations and death certificates. The medications received during index hospitalisation and follow-up treatments were also recorded.

All data after enrolment were recorded prospectively following the protocol of the ABC Study on Heart Disease.<sup>11</sup> According to the protocol, baseline data and follow-up data were recorded in two different datasheets. For the present analysis, the datasheets were merged after completion of 20 years of follow-up.

### 2.3 | Causes of death

The primary clinical outcome was 20-year all-cause mortality. The secondary outcomes were modes of death, which were classified into the following categories: coronary artery disease and/or heart failure progression (CAD/HF); sudden cardiac death (SCD), defined as witnessed, out-of-hospital death within 1 hour after the onset of acute symptoms or unwitnessed, unexpected death (eg, during sleep) in patients with good health 24 hours before the event<sup>15</sup>; other cardiovascular (other CV) causes; and non-cardiac death causes. The patients were examined and the cause of death was determined by two clinical researchers with no knowledge of the patients' baseline data.

### 2.4 | Statistical analysis

The accrued variables were analysed as continuous variables or proportions. Log transformations were applied to correct for positively skewed distributions as appropriate. Measured variables were analysed using the unpaired Student's *t* test, and categorical variables using Pearson's  $\chi^2$  test. If a patient dropped out prior to 20 years of follow-up, her/his data were censored at that time. Survival curves were constructed using cumulative hazards.<sup>16</sup> We compared incidence rates (IRs) using Mantel-Haenszel estimates of the rate ratio. Interaction analysis for lipid versus age and gender was also performed.<sup>17</sup> The risk ratios (RRs) estimated in the analysis and graphic representations of the mortality were obtained using lipid values as dichotomous variables, with the 50th percentile as a cut-off.

Log-transformed continuous variables were used for global mortality risk estimation using Cox regression models and scaled Schoenfeld residuals were used to test the proportionality assumption with 95% confidence intervals (CIs). Competitive risk regression models with the Fine-Gray method using the same log-transformed continuous variables were set-up to analyse each of the four modes of death. The strength of an association was expressed as  $\beta$  coefficient  $\pm$  SE. The predictive power of lipid values as continuous variables with regard to mortality was also estimated. Based on survival regression, a postestimation prediction of mortality was carried out and graphically presented along with the appropriate *P*-values calculated by the survival regression. Unless otherwise indicated,

two-tailed *P*-values  $< .05$  were considered significant. Statistical analyses were performed using STATA 14.

## 3 | RESULTS

All enrolled patients completed the follow-up unless pre-empted by death, except three patients for whom survival time was censored before 20 years; two withdrew consent and one moved overseas (Figure 1). Table 1 compares the demographic and baseline clinical characteristics of the patients according to plasma TC level at admission in relation to the median value of 208 mg/dL.

At enrolment, the two groups did not differ in most of the clinical characteristics. However, females were more frequent among patients with higher TC levels. In addition, these patients had higher BMI, used alcohol less frequently and had higher blood haemoglobin values. Patients who had TC  $>208$  mg/dL at admission also had higher LDL and TG levels and lower HDL levels.

By the end of 20 years of follow-up, 437 (74%) of the patients discharged alive had died: 105 (24%) from CAD/HF, 90 (21%) SCD, 71 (16%) other CV causes and 171 (39%) non-cardiac death (Figure 1). The IR of all-cause mortality throughout follow-up after acute coronary syndrome was approximately 66.7 (95% CI 60.7–73.3) cases/1000 person-years. Unexpectedly, the IR was not associated with the baseline plasma lipids (Table S1). Cumulative hazard estimate curves for 20-year all-cause mortality risk according to baseline plasma lipid levels are illustrated in Figure 2 and Figure S1.

The final survival analysis accounted for competitive risks for each of the main four causes of death, revealing that the positive association of baseline TC, LDL and TG levels and the negative association of HDL level with long-term CAD/HF mortality were not statistically significant in the unadjusted model, a model adjusted for age and gender or the fully adjusted model (Table 2). The analysis also showed a lack of consistently positive or negative association between TC and LDL and other causes of cardiac mortality. Only the hazard of non-cardiac death was consistently higher among patients with TC or LDL values less than or equal to median values at admission in all models (Table 2B).

## 4 | DISCUSSION

This prospective three-centre study of an unselected real-world patient discharged alive after acute coronary syndrome showed that baseline plasma TC, LDL, HDL and TG levels are not associated with long-term global mortality. The association with modes of death showed an independent inverse association between TC and LDL and non-cardiac death. The same findings were reported in our research letter.<sup>18</sup>

The results are consistent for lipid measurements at admission or after 1 week of hospitalisation. Furthermore, the associations were independent of anti-lipid treatment, suggesting that the core prognostic issue lies on the lipid levels per se.

Variable	Overall sample (n = 589)	TC ≤208 mg/ dL (n = 295)	TC >208 mg/dL (n = 294)	P values
Median age, years	67 (58-74)	67 (59-75)	66 (58-73)	.47
Gender, female	29.2	22	36	<.0001
Education above primary school	26	29	23	.37
Median body mass index, kg/m <sup>2</sup>	26 (24-28)	25 (23-27)	26 (24-29)	.0001
Smoking habit <sup>a</sup>	67	71	64	.09
Alcohol use	74	80	68	.001
Hypertension	47	51	44	.08
Diabetes mellitus	22	22	23	.68
Median systolic blood pressure, mm Hg	120 (110-130)	120 (110-130)	120 (110-135)	.19
Median diastolic blood pressure, mm Hg	80 (70-80)	75 (70-80)	80 (70-80)	.50
Median heart rate, beats/min	71 (60-82)	72 (60-81)	70 (61-82)	.54
Non-ST elevation ACS	38	38	39	.79
Killip class >1	33	34	33	.75
LVEF (%) (n = 500)	52 (45-61)	53 (45-60)	52 (45-61)	.73
Hb, g/dL	14 (13-15)	13 (12-15)	14 (13-15)	.0001
Blood glucose level, mg/dL	119 (100-158)	117 (98-153)	122 (103-172)	.06
Serum creatinine level, mg/dL	0.9 (0.8-1.1)	0.9 (0.8-1.1)	0.9 (0.8-1.1)	.95
CK-MB peak <sup>b</sup> , U/L	102 (43-203)	100 (42-186)	104 (34-214)	.15
Serum lipids <sup>b</sup> , mg/dL				
Total cholesterol				
At admission	208 (179-243)	179 (159-193)	243 (225-264)	<.0001
At discharge	198 (174-224)	177 (155-192)	220 (204-245)	<.0001
LDL <sup>c</sup>				
At admission	133 (108-157)	108 (91-158)	157 (144-178)	<.0001
At discharge	125 (106-147)	109 (93-122)	143 (128-163)	<.0001
HDL				
At admission	44 (37-51)	42 (36-51)	45 (39-52)	.005
At discharge	39 (33-47)	37 (32-46)	40 (33-49)	.01
TGs				
At admission	127 (93-178)	109 (81-147)	155 (112-218)	<.0001
At discharge	146 (111-188)	129 (102-162)	162 (124-212)	<.0001

Note: The values are presented as medians and interquartile ranges or percentages.

Abbreviations: ACS, acute coronary syndrome; CK-MB, creatine kinase-MB isoenzyme; Hb, haemoglobin; HDL, high-density lipoprotein cholesterol; LDH, lactate dehydrogenase-1 isoenzyme; LDL-C, low-density lipoprotein-cholesterol; LVEF, left ventricular ejection fraction; TC, total cholesterol; TG, triglyceride.

<sup>a</sup>Previous smokers and currently smoking patients.

<sup>b</sup>P-values were calculated using log-transformed data.


<sup>c</sup>Calculated using modified Friedewald formula.

**TABLE 1** Baseline characteristics of patients with acute coronary syndrome according to the baseline total cholesterol level


The general view is that an elevated level of plasma of TC and LDL is a major risk factor for developing atherosclerotic cardiovascular disease (CVD).<sup>2-4</sup> Interestingly, our results demonstrated

that neither total nor LDL-cholesterol was elevated at the time of admission with acute coronary syndrome as it should be expected according to that view. Low or normal TC and LDL-C in patients

**Panel (A)**



**Panel (B)**



**FIGURE 2** Cumulative hazard estimate curves for 20-year all-cause mortality risk. A, Cumulative hazard estimate according to day 1 plasma lipid levels. B, Estimated prediction. HDL, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; TG, triglyceride. *P*-values were calculated by unadjusted Cox regression models using log-transformed continuous variables

with CVD has been reported by other researchers.<sup>19,20</sup> Recently, the general view has been questioned.<sup>5-7</sup> As reported by Ravnskov et al,<sup>7</sup> there are many observations and experiments contradicting

that high TC or LDL-C causes atherosclerosis and CVD, and several recent observations have supported their view. For instance, six recent follow-up studies including almost 700 000 individuals of

**TABLE 2** Cox regression analysis of all-cause mortality risk (A) and competing risk regression analysis for the main causes of death (B) according to baseline plasma lipid levels

Variable	Adjusted for age and gender			Fully adjusted <sup>a</sup>			Fully adjusted <sup>b</sup>		
	$\beta \pm$ Robust SE	Z	P	$\beta \pm$ Robust SE	Z	P	$\beta \pm$ Robust SE	Z	P
<b>(A) Cox regression analysis</b>									
All-cause mortality (n = 437)									
Total cholesterol									
At admission	0.46 ± 0.22	-2.07	.04	0.58 ± 0.22	-2.62	.01	0.44 ± 0.24	-1.86	.06
At discharge	0.55 ± 0.27	-2.02	.04	0.50 ± 0.27	-1.86	.06	0.32 ± 0.28	-1.14	.25
LDL									
At admission	0.33 ± 0.16	-2.02	.04	0.43 ± 0.17	-2.58	.01	0.32 ± 0.18	-1.82	.07
At discharge	0.32 ± 0.22	-1.46	.14	0.34 ± 0.22	-1.58	.12	0.20 ± 0.23	-0.86	.39
HDL									
At admission	0.41 ± 0.18	-2.20	.03	0.36 ± 0.19	-1.89	.06	0.35 ± 0.19	-1.87	.06
At discharge	0.64 ± 0.20	-3.22	<.0001	0.46 ± 0.21	-2.21	.03	0.41 ± 0.21	-1.98	.05
TGs									
At admission	0.11 ± 0.10	1.04	.30	0.06 ± 0.11	0.58	.56	0.10 ± 0.11	0.90	.37
At discharge	0.11 ± 0.14	0.81	.42	0.02 ± 0.14	0.16	.87	0.07 ± 0.14	0.49	.62
<b>(B) Competing risk regression</b>									
CAD/HF mortality (n = 105)									
Total cholesterol									
At admission	0.78 ± 0.48	1.63	.10	0.78 ± 0.48	1.63	.10			
At discharge	0.33 ± 0.57	0.57	.57	0.57 ± 0.56	1.01	.31			
LDL									
At admission	0.66 ± 0.37	1.76	.08	0.69 ± 0.39	1.77	.08			
At discharge	0.55 ± 0.46	1.20	.23	0.74 ± 0.46	1.60	.11			
HDL									
At admission	-0.66 ± 0.38	-1.74	.08	-0.51 ± 0.41	-1.24	.22			
At discharge	-0.72 ± 0.39	-1.85	.06	-0.54 ± 0.42	-1.29	.20			
TGs									
At admission	0.41 ± 0.20	2.01	.05	0.33 ± 0.21	1.59	.11			
At discharge	0.19 ± 0.27	0.69	.49	0.05 ± 0.27	0.19	.85			
SCD (n = 90)									
Total cholesterol									
At admission	0.58 ± 0.52	1.12	.26	0.83 ± 0.46	1.83	.07			
At discharge	0.27 ± 0.64	0.42	.67	0.74 ± 0.59	1.25	.21			
LDL									
At admission	0.44 ± 0.41	1.09	.28	0.62 ± 0.38	1.62	.10			
At discharge	0.46 ± 0.52	0.89	.38	0.76 ± 0.50	1.52	.13			
HDL									
At admission	-0.41 ± 0.44	-0.94	.35	-0.35 ± 0.46	-0.76	.45			
At discharge	-1.11 ± 0.44	-2.53	.01	-0.76 ± 0.46	-1.63	.10			
TGs									
At admission	0.10 ± 0.23	0.45	.65	0.25 ± 0.22	1.17	.24			
At discharge	0.06 ± 0.31	0.20	.85	0.12 ± 0.31	0.37	.71			

(Continues)

TABLE 2 (Continued)

Variable	Adjusted for age and gender			Fully adjusted <sup>a</sup>			Fully adjusted <sup>b</sup>		
	$\beta \pm$ Robust SE	Z	P	$\beta \pm$ Robust SE	Z	P	$\beta \pm$ Robust SE	Z	P
Other CV causes (n = 71)									
Total cholesterol									
At admission	-0.63 ± 0.46	-1.35	.18	-0.44 ± 0.50	-0.87	.38			
At discharge	-0.68 ± 0.60	-1.13	.26	-0.56 ± 0.65	-0.87	.39			
LDL									
At admission	-0.38 ± 0.31	-1.21	.23	-0.23 ± 0.36	-0.66	.51			
At discharge	-0.68 ± 0.46	-1.48	.14	-0.62 ± 0.51	-1.22	.22			
HDL									
At admission	0.15 ± 0.50	0.30	.77	0.34 ± 0.49	0.70	.49			
At discharge	0.22 ± 0.48	0.45	.65	0.49 ± 0.57	0.86	.39			
TGs									
At admission	-0.12 ± 0.24	-0.50	.61	-0.30 ± 0.26	-1.16	.25			
At discharge	0.27 ± 0.31	0.89	.37	0.08 ± 0.34	0.24	.81			
Non-cardiac death (n = 171)									
Total cholesterol									
At admission	-0.86 ± 0.36	-2.40	.02	-1.12 ± 0.39	-2.86	<.0001			
At discharge	-0.28 ± 0.42	-0.66	.51	-0.53 ± 0.46	-1.15	.25			
LDL									
At admission	-0.71 ± 0.27	-2.67	.01	-0.88 ± 0.28	-3.11	<.0001			
At discharge	-0.40 ± 0.33	-1.20	.23	-0.55 ± 0.36	-1.54	.12			
HDL									
At admission	0.38 ± 0.28	1.38	.17	0.25 ± 0.29	0.87	.39			
At discharge	0.64 ± 0.31	2.05	.04	0.35 ± 0.33	1.07	.29			
TGs									
At admission	-0.28 ± 0.18	-1.60	.11	-0.32 ± 0.19	-1.64	.10			
At discharge	-0.18 ± 0.22	-0.84	.40	-0.11 ± 0.23	-0.48	.64			

Note: P-values were calculated for log-transformed data.

Abbreviations: CAD, coronary artery disease; CV, cardiovascular; HDL, high-density lipoprotein cholesterol; HF, heart failure; LDL-C, low-density lipoprotein-cholesterol; SCD, sudden cardiac death; SE, standard error; TG, triglyceride.

<sup>a</sup>Adjusted for age, gender, smoking, diabetes mellitus, hypertension, heart failure at admission, STEMI and hospital site.

<sup>b</sup>Adjusted for age, gender, smoking, diabetes mellitus, hypertension, heart failure at admission, STEMI, hospital site and the use of statins.

all ages from various countries have shown that neither TC nor LDL-C is a risk factor of mortality, neither among statin-treated patients nor among untreated individuals.<sup>21-25</sup> In fact, as shown by our results as well, low values are associated with increased total mortality. This finding challenges the view that high cholesterol is the cause of early death from CVD as well because the commonest cause of death in most countries is CVD. Furthermore, in the study by Ravnskov et al,<sup>26</sup> CVD mortality was recorded as well in seven of the 19 studies they had included in their review, and in six of them, LDL-C was not associated with CVD mortality and in one of them, CVD mortality was highest among those with the lowest LDL-C.

In many studies, increased serum lipids and lipoproteins are associated with a higher risk of total and cardiac mortality.<sup>27-35</sup>

However, absence of an association, or even an inverse association, has been reported,<sup>5-7</sup> especially with increasing age.<sup>26,36</sup> In accordance, prior observational studies have reported paradoxically better outcomes in hypercholesterolaemic patients who sustain acute coronary syndrome, the so-called 'cholesterol paradox'.<sup>20,37-39</sup>

The occurrence of acute coronary syndrome is accompanied by transient changes in the plasma lipid profile, including decreases in TC, LDL and HDL levels and increases in plasma TG.<sup>40,41</sup> The prognostic value of plasma lipids at admission was investigated in prior studies, and a hypercholesterolaemia paradox has also been observed.<sup>8-10,20,42-45</sup>

Importantly, the majority of these reports were performed in the short- to intermediate term; the longest was approximately 3 years.

Furthermore, a single LDL or TG level at admission was used, accordingly, the effect of the changes in their levels on clinical outcomes could not be assessed. Notably, these reports tended to focus on total mortality.<sup>8-10,20,42-45</sup>

Although it was not significant, we also observed the negative trend (hypercholesterolaemia paradox). Our different prognostic results support the assumption of the presence of other modifiable risk factors, other than cholesterol levels, that deliberates this risk in the majority of patients and may explain why patients develop myocardial infarction despite a low LDL level<sup>19,39</sup> or why a considerable proportion of major adverse events are still not prevented by aggressive lipid-lowering treatment.<sup>46</sup> We also observed during the long-term follow-up that non-cardiac death was more prevalent, and an inverse association with plasma lipid levels was observed in concordance with previous reports.<sup>5,47,48</sup> This observation is clinically relevant if we consider that the non-cardiac mortality rate after acute coronary syndrome has progressively increased in recent years.<sup>49,50</sup> We could assume that the improvement in CV treatment tends to reduce CV mortality, allowing non-cardiac disorders and their complications to prevail. In agreement with our findings, other authors have reported an unexplained absence of an independent association between cholesterol and stroke mortality, especially at older ages or in the presence of higher blood pressures.<sup>32</sup> Age is also a considerable factor, as the median age of our cohort at the time of admission was approximately 67 years, and it is understandable that the prognostic role of plasma lipids changes with the ageing of the population. In a systematic review, Ravnskov et al<sup>26</sup> reported a lack of an association or inverse association between LDL and mortality in elderly people. In short, our study provides new clinical insight and perspective into the long-term prognostic significance of admission plasma lipid levels in survivors of acute coronary syndrome.

The present prospective long-term study revealed that baseline plasma lipid levels during acute coronary syndrome seem not to be associated with long-term global mortality. Only an independent inverse association between TC and LDL and non-cardiac death has been observed.

## 5 | STUDY LIMITATIONS

A major limitation of the ABC study of acute coronary syndrome was that, at the time of patient enrolment, percutaneous coronary angioplasty was not yet used to reopen coronary arteries in patients with STEMI. Thus, it remains uncertain whether the results may have been altered by early mechanical reperfusion. Although Cho et al<sup>43</sup> reported that admission LDL-cholesterol level was not an independent predictor of mortality at 12 months among 9571 patients with acute myocardial infarction who had a percutaneous coronary intervention (PCI). Pres et al<sup>45</sup> also reported that LDL level at admissions was not associated with increased in-hospital mortality in non-diabetic patients treated with PCI for STEMI, and Al-Mallah et al<sup>8</sup> reported an inverse association, despite that more than 60% of their patients have been subjected to PCI or coronary artery bypass graft surgery. Furthermore, statin treatment was much less

commonly used at the beginning of the study period (1995-1998) and steadily increased from the 1st to the 20th year of follow-up in accordance with guideline revisions over that time period. Finally, as the patients in this study were all Caucasians, we cannot generalise the present findings to other populations and ethnic groups.

## ACKNOWLEDGEMENTS

The authors thank Paola Michelazzo, RN, Jessica Civiero, RN, Lauro Trevisan, RN, and nurses from the emergency care units for their assistance with patient management. We thank Rosa Palmieri, MD, Mario Baggio, RN, Daniela Donadel, RN, and Raffaella Frare, RN, for their assistance with handling the data. We thank Renzo De Toni, PhD, Patrizio Buttazzi, PhD, and the general laboratory personnel of the Conegliano, Adria, and Bassano General Hospitals for assistance collecting laboratory data.

## DISCLOSURES

None.

## AUTHOR CONTRIBUTIONS

Dr G. Berton and Dr F. Cavuto designed the study. Dr R. Cordiano and Dr F. Bagato contributed to the original data collection. Dr F. Cavuto and Dr R. Cordiano contributed to data handling and patient follow-up. Dr G. Berton and Dr HT Mahmoud contributed to the data analysis and interpretation, tables and figures preparation and manuscript preparation. All authors contributed to ensuring the accuracy of the data analysis.

## ORCID

Giuseppe Berton  <https://orcid.org/0000-0001-9965-0932>

Heba T. Mahmoud  <https://orcid.org/0000-0001-6171-5630>

## REFERENCES

1. World Health Organization. *Global health estimates 2016: disease burden by cause, age, sex, by country and by region, 2000-2016*. Geneva, Switzerland: World Health Organization; 2018.
2. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. *Cell*. 2015;161(1):161-172.
3. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Rev Esp Cardiol (Engl Ed)*. 2017;70(2):115.
4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. *J Am Coll Cardiol*. 2019;73(24):3168-3209.
5. Hamazaki T, Okuyama H, Ogushi Y, Hama R. Towards a paradigm shift in cholesterol treatment. A re-examination of the cholesterol issue in Japan. *Ann Nutr Metab*. 2015;66(Suppl 4):1-116.
6. Petursson H, Sigurdsson JA, Bengtsson C, Nilsen TI, Getz L. Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study. *J Eval Clin Pract*. 2012;18(1):159-168.
7. Ravnskov U, de Lorge M, Diamond DM, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. *Expert Rev Clin Pharmacol*. 2018;11(10):959-970.

8. Al-Mallah MH, Hatahet H, Cavalcante JL, Khanal S. Low admission LDL-cholesterol is associated with increased 3-year all-cause mortality in patients with non ST segment elevation myocardial infarction. *Cardiol J*. 2009;16(3):227-233.
9. Khawaja OA, Hatahet H, Cavalcante J, Khanal S, Al-Mallah MH. Low admission triglyceride and mortality in acute coronary syndrome patients. *Cardiol J*. 2011;18(3):297-303.
10. Reddy VS, Bui QT, Jacobs JR, Begelman SM, Miller DP, French WJ. Relationship between serum low-density lipoprotein cholesterol and in-hospital mortality following acute myocardial infarction (the lipid paradox). *Am J Cardiol*. 2015;115(5):557-562.
11. Berton G, Citro T, Palmieri R, Petuccio S, De Toni R, Palatini P. Albumin excretion rate increases during acute myocardial infarction and strongly predicts early mortality. *Circulation*. 1997;96(10):3338-3345.
12. Berton G, Cordiano R, Cavuto F, Giacomini G, De Toni R, Palatini P. Predictors of ten-year event-free survival in patients with acute myocardial infarction (from the Adria, Bassano, Conegliano, and Padova Hospitals [ABC] study on myocardial infarction). *Am J Cardiol*. 2012;109(7):966-975.
13. Pasternak RC, Braunwald E, Sobel BE. Acute myocardial infarction. In: Braunwald E, ed. *Heart disease: A textbook of cardiovascular medicine*, 5th ed. Philadelphia, PA: WB Saunders; 1997:1198-1191.
14. Mizoguchi T, Edano T, Koshi T. A method of direct measurement for the enzymatic determination of cholesteryl esters. *J Lipid Res*. 2004;45(2):396-401.
15. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J*. 2015;36(41):2793-2867.
16. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. *Circulation*. 2016;133(6):601-609.
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94(446):496-509.
18. Berton G, Cordiano R, Mahmoud HT, Bagato F, Cavuto F, Pasquinnucci M. Plasma lipid levels during ACS: association with 20-year mortality: The ABC-5\* Study on Heart Disease. *Eur J Prev Cardiol*. 2019;2047487319873061. [Epub ahead of print]. <https://doi.org/10.1177/2047487319873061>
19. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136 905 hospitalizations in Get With The Guidelines. *Am Heart J*. 2009;157(1):111-117.e2.
20. Martin SS, Faridi KF, Joshi PH, et al. Remnant lipoprotein cholesterol and mortality after acute myocardial infarction: further evidence for a hypercholesterolemia paradox from the TRIUMPH Registry. *Clin Cardiol*. 2015;38(11):660-667.
21. Bendzala M, Sabaka P, Caprnda M, et al. Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women. *Wien Klin Wochenschr*. 2017;129(21-22):793-798.
22. Charlton J, Ravindrarajah R, Hamada S, Jackson SH, Gulliford MC. Trajectory of total cholesterol in the last years of life over age 80 years: cohort study of 99 758 participants. *J Gerontol A Biol Sci Med Sci*. 2017;73(8):1083-1089.
23. Gnanenthiran SR, Ng ACC, Cumming R, et al. Low total cholesterol is associated with increased major adverse cardiovascular events in men aged  $\geq 70$  years not taking statins. *Heart*. 2019. <https://doi.org/10.1136/heartjnl-2019-315449>
24. Sung K-C, Huh JH, Ryu S, et al. Low levels of low-density lipoprotein cholesterol and mortality outcomes in non-statin users. *J Clin Med*. 2019;8(10):1571.
25. Wang M-C, Hu H-Y, Lin I-F, Chuang J-T. Plasma lipid concentrations and survival in geriatric population: a retrospective cohort study. *Medicine*. 2019;98(49):e18154.
26. Ravnskov U, Diamond DM, Hama R, et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. *BMJ Open*. 2016;6(6):e010401.
27. Stamler J, Daviglius ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. *JAMA*. 2000;284(3):311-318.
28. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106(25):3143-3421.
29. Ivanovic B, Pinkham CA. Relationships between serum lipids and subsequent mortality in an insured population. *J Insur Med*. 2003;35(1):11-16.
30. Johansson S, Wilhelmsen L, Lappas G, Rosengren A. High lipid levels and coronary disease in women in Goteborg—outcome and secular trends: a prospective 19 year follow-up in the BEDA\*study. *Eur Heart J*. 2003;24(8):704-716.
31. Psaty BM, Anderson M, Kronmal RA, et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. *J Am Geriatr Soc*. 2004;52(10):1639-1647.
32. Prospective Studies C, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet*. 2007;370(9602):1829-1839.
33. Horne BD, Muhlestein JB, Anderson JL. Letter by Horne et al. Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Survey III (NHANES-III)". *Circulation*. 2015;131(19):e472.
34. Orozco-Beltran D, Gil-Guillen VF, Redon J, et al. Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study. *PLoS ONE*. 2017;12(10):e0186196.
35. Abdullah SM, Defina LF, Leonard D, et al. Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. *Circulation*. 2018;138(21):2315-2325.
36. Bathum L, Depont Christensen R, Engers Pedersen L, Lyngsie Pedersen P, Larsen J, Nexoe J. Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register study. *Scand J Prim Health Care*. 2013;31(3):172-180.
37. Wang TY, Newby LK, Chen AY, et al. Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. *Clin Cardiol*. 2009;32(9):E22-E28.
38. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. *Circulation*. 2000;101(22):2557-2567.
39. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. *Arch Intern Med*. 2003;163(19):2345-2353.
40. Khan HA, Alhomida AS, Sobki SH. Lipid profile of patients with acute myocardial infarction and its correlation with systemic inflammation. *Biomark Insights*. 2013;8:1-7.
41. Barth JH, Jackson BM, Farrin AJ, et al. Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE

- ROCKET study data and a comparative literature review. *Clin Chem*. 2010;56(10):1592-1598.
42. Nozue T. Low-density lipoprotein cholesterol level and statin therapy in patients with acute myocardial infarction (cholesterol paradox). *Circ J*. 2016;80(2):323-324.
  43. Cho KH, Jeong MH, Ahn Y, et al. Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox). *Am J Cardiol*. 2010;106(8):1061-1068.
  44. Reindl M, Reinstadler SJ, Feistritzer H-J, et al. Relation of low-density lipoprotein cholesterol with microvascular injury and clinical outcome in revascularized ST-elevation myocardial infarction. *J Am Heart Assoc*. 2017;6(10):e006957.
  45. Pres D, Gašior M, Lekston A, et al. Relationship between low-density lipoprotein cholesterol level on admission and in-hospital mortality in patients with ST-segment elevation myocardial infarction, with or without diabetes, treated with percutaneous coronary intervention. *Kardiol Pol*. 2010;68(9):1005-1012.
  46. Rockberg J, Jorgensen L, Taylor B, Sobocki P, Johansson G. Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment. *Prev Med Rep*. 2017;6:203-209.
  47. Newson RS, Felix JF, Heeringa J, Hofman A, Wittteman JC, Tiemeier H. Association between serum cholesterol and noncardiovascular mortality in older age. *J Am Geriatr Soc*. 2011;59(10):1779-1785.
  48. Berton G, Cordiano R, Cavuto F, Bagato F, Mahmoud HT, Pasquinucci M. Association between plasma lipid levels during acute coronary syndrome and long-term malignancy risk. The ABC-4\* Study on Heart Disease. *J BMC cardiovascular disorders*. 2019;19(1):119.
  49. Berton G, Cordiano R, Cavuto F, Bagato F, Segafredo B, Pasquinucci M. Neoplastic disease after acute coronary syndrome: incidence, duration, and features: the ABC-4\* Study on Heart Disease. *J Cardiovasc Med (Hagerstown)*. 2018;19(10):546-553.
  50. Spoon DB, Psaltis PJ, Singh M, et al. Trends in cause of death after percutaneous coronary intervention. *Circulation*. 2014;129(12):1286-1294.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Berton G, Cordiano R, Mahmoud HT, Palmieri R, Cavuto F, Pasquinucci M. Baseline plasma lipid levels in patients with acute coronary syndrome: Association with 20-year mortality. The ABC-5a Study on Heart Disease. *Int J Clin Pract*. 2020;74:e13492. <https://doi.org/10.1111/ijcp.13492>